CBS 2019
CBSMD教育中心
English

肺动脉高压

科研文章

荐读文献

Circulating Plasma microRNAs In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Haemodynamic definitions and updated clinical classification of pulmonary hypertension Management of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation Pulmonary Artery Denervation: A New, Long-Awaited Interventional Treatment for Combined Pre- and Post-Capillary Pulmonary Hypertension? Pulmonary Hypertension in Heart Failure: Pathophysiology, Pathobiology, and Emerging Clinical Perspectives Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension Pulmonary hypertension is associated with an increased incidence of NAFLD: A retrospective cohort study of 18,910 patients A Notch3-Marked Subpopulation of Vascular Smooth Muscle Cells Is the Cell of Origin for Occlusive Pulmonary Vascular Lesions. Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension
|<< 1 2 3 4 5 6 7 8 >>|

Original Research2019 Jul;12(7):e005103.

JOURNAL：Circ Cardiovasc Qual Outcomes. Article Link

Comparative Effectiveness of β-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients

Shavadia JS, Holmes DN, Thomas L et al. Keywords: 3-year post-MI survivors; β-blocker; elderly; observational study; long-term cardiovascular outcomes

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top